Compare Canopy Growth Corp (CGC) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Goldman Sachs Group Inc — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Goldman Sachs Group Inc trades at $1,034.77 (market cap $301.19B). The key difference: Goldman Sachs Group Inc is far larger — about 715.2× Canopy Growth Corp's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CGC | GS | |
|---|---|---|
Market Cap | $421.10M | $301.19B |
Sector | Health | Financials |
52-Week High | $1.92 | $1.15K |
52-Week Low | $0.86 | $715.95 |
Enterprise Value | $378.55M | — |
Volume | — | 2,592,735 |
Dividend Yield | — | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.025, up 7.66% with bullish technical signals. The company shows improving fundamentals with Q1 2027 revenue growth of 13% and narrowing losses. Recent acquisitions and cost-cutting initiatives support expansion in medical and European cannabis markets. The stock trades below book value (P/B 0.86) while maintaining a P/S ratio of 1.71.
CGC presents a high-risk turnaround opportunity with improving balance sheet metrics and positive revenue momentum. However, persistent negative earnings and cash flow challenges require careful monitoring. Analyst sentiment remains divided with 33% buy ratings, reflecting the speculative nature of cannabis sector investments amid ongoing regulatory uncertainty.
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
